TIDMC4XD
RNS Number : 8268I
C4X Discovery Holdings PLC
29 November 2018
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4XD enters discovery partnership with state-of-the-art
artificial intelligence company, GTN Ltd.
Partnership to maximise insights from shape-based chemistry and
generate novel drug candidates in neurodegeneration
29 November 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that it has entered
into a drug discovery partnership with GTN Ltd. ("GTN"), a
disruptive new player in the field of drug discovery artificial
intelligence ("AI"), initially focussing on identifying potential
small molecule hits against a high-value neurodegeneration
target.
Artificial Intelligence is expected to revolutionise the drug
discovery industry. GTN is at the forefront of the field, using
deep-learning techniques and quantum physics to simulate, filter
and search for molecules that are hidden from traditional
technologies. However, over-simplistic representation of molecules
is a key challenge for the application of artificial intelligence
to problems of medicinal chemistry, resulting in suboptimal
property prediction and thus results. In order to address this
"representation problem", C4XD, using its conformational analysis
platform Conformetrix, will provide GTN with world-leading
molecular descriptors for use in its in-silico discovery platform.
By combining both technologies, the collaboration will aim to
unlock new areas of chemical space and identify novel small
molecules.
This discovery partnership adds another high value programme to
C4XD's portfolio. It represents continued progress against C4XD's
strategy of accessing cutting-edge, high impact technologies
through productive partnerships that will accelerate growth of its
diversified portfolio of commercially attractive assets.
Dr Craig Fox, CSO of C4X Discovery, said: "Strategic
partnerships represent a critical component of our strategy and we
are delighted to be collaborating with the team at GTN on this
exciting project. Leveraging the clear synergies that exist between
our Conformetrix platform and GTN's in-silico discovery technology,
we aim to solve the representation problem and enable pioneering
research into unexplored chemical space against a commercially
attractive neurodegeneration target. We are looking forward to
seeing the results of this project."
Noor Shaker, CEO of GTN, said: "We are excited to be working
with C4XD. This partnership is a great milestone for GTN as we
expand the capabilities of our proprietary quantum machine learning
platform. GTN will deploy its platform to discover novel, high
quality chemicals and accelerate the discovery process. GTN's
unique approach to quantum representation of molecules and advance
machine learning plays very nicely with C4XD's molecular
descriptors. It is a key component of GTN's strategy to form close
collaborations with biotechs and pharmaceutical companies and we
hope that this is the start of a growing relationship with C4XD. We
are looking forward to a productive collaboration with C4XD."
-ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer +44 (0)7801 865 803
GTN Ltd
Noor Shaker, Chief Executive Officer +44 (0)7742 213 881
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886
2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards the pre-clinical licensing
discussions. In selecting new targets and executing new drug
discovery programmes, C4X Discovery focuses on high-value disease
areas that are the subject of significant licensing activity and
will continue to also maximise value from opportunistic areas such
as addiction and diabetes. The Company recently signed a licensing
agreement with Indivior for a pre-clinical addiction programme
worth up to $294m.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
About GTN Ltd
GTN's mission is to be the leader in the discovery of
high-quality, novel drug candidates. We are helping pharmaceutical
companies accelerate drug discovery and do it more efficiently at a
fraction of the cost through our proprietary technology. We are
building the software technology to efficiently access the full
drug-like space, i.e. 10^60, and to more accurately predict
chemical activities. We do this through our advanced technology to
simulate, evaluate and search for highly effective small molecule
drug candidates. Our patent-pending technology, Generative
Tensorial Networks, combines ideas from machine learning and
quantum physics in order to provide the most accurate
representation of chemicals for predicting ADMET, binding affinity
and physchem properties, as well as the most advanced technology
for discovery of completely novel compounds.
GTN received the CogX UK Rising Star award for Outstanding
Achievement in Machine Learning handed to the CEO by the British
Prime Minister and was recently featured in WIRED magazine. For
additional information please go to: www.gtn.ai
This announcement contains inside information for the purposes
of Article 7 of Regulatory (EU) No596/2014
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTPGGWWGUPRGMR
(END) Dow Jones Newswires
November 29, 2018 02:00 ET (07:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Mar 2024 to Apr 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2023 to Apr 2024